DESTINY-Endometrial01 Phase 3 Trial Of ENHERTU® Initiated As First-Line Therapy In Patients With HER2 Expressing Primary Advanced Or Recurrent Endometrial Cancer
RefinitivOkuma süresi: 1 dakikadan kısa
Daiichi Sankyo Co Ltd 
4568:
DESTINY-ENDOMETRIAL01 PHASE 3 TRIAL OF ENHERTU® INITIATED AS FIRST-LINE THERAPY IN PATIENTS WITH HER2 EXPRESSING PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun